Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Responder analysis for improvement in 6‐min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency

Tools
- Tools
+ Tools

Anker, Stefan D., Ponikowski, Piotr, Khan, Muhammad Shahzeb, Friede, Tim, Jankowska, Ewa A., Fabien, Vincent, Goehring, Udo‐Michael, Metra, Marco, Piña, Ileana L., Coats, Andrew J. S., Rosano, Giuseppe, Dorigotti, Fabio, Comin‐Colet, Josep, Van Veldhuisen, Dirk J., Filippatos, Gerasimos S. and Butler, Javed (2022) Responder analysis for improvement in 6‐min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency. European Journal of Heart Failure, 24 (5). pp. 833-842. doi:10.1002/ejhf.2491 ISSN 1879-0844. [ 🗎 Public]. [ (✓) hoa:511 ]

[img]
Preview
PDF
WRAP-Responder-improvement-6-min-walk-ferric-heart-failure-ejection-fraction-iron-2022.pdf - Published Version - Requires a PDF viewer.
Available under License Creative Commons Attribution 4.0.

Download (4Mb) | Preview
Official URL: https://doi.org/10.1002/ejhf.2491

Request Changes to record.

Abstract

Aim: Improving functional capacity is a key goal in heart failure (HF). This pooled analysis of FAIR‐HF and CONFIRM‐HF assessed the likelihood of improvement or deterioration in 6‐min walk test (6MWT) among iron‐deficient patients with chronic HF with reduced ejection fraction (HFrEF) receiving ferric carboxymaltose (FCM).

Methods and results: Data for 760 patients (FCM: n = 454; placebo: n = 306) were analysed. The proportions of patients receiving FCM or placebo who had ≥20, ≥30, and ≥40 m improvements or ≥10 m deterioration in 6MWT at 12 and 24 weeks were assessed. Patients receiving FCM experienced a mean (standard deviation) 31.1 (62.3) m improvement in 6MWT versus 0.1 (77.1) m improvement for placebo at week 12 (difference in mean changes 26.8 [16.6;37.0]). At week 12, the odds [95% confidence interval] of 6MWT improvements of ≥20 m (odds ratio 2.16 [1.57–2.96]; p < 0.0001), ≥30 m (2.00 [1.44–2.78]; p < 0.0001), and ≥40 m (2.29 [1.60–3.27]; p < 0.0001) were greater with FCM versus placebo, while the odds of a deterioration ≥10 m were reduced with FCM versus placebo (0.55 [0.38–0.80]; p = 0.0019). Among patients who experienced 6MWT improvements of ≥20, ≥30, or ≥40 m with FCM at week 12, more than 80% sustained this improvement at week 24.

Conclusion: Ferric carboxymaltose resulted in a significantly higher likelihood of improvement and a reduced likelihood of deterioration in 6MWT versus placebo among iron‐deficient patients with HF. Of the patients experiencing clinically significant improvements at week 12, the majority sustained this improvement at week 24. These results are supportive of FCM to improve exercise capacity in HF.

Item Type: Journal Article
Subjects: R Medicine > RC Internal medicine
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
SWORD Depositor: Library Publications Router
Library of Congress Subject Headings (LCSH): Heart failure -- Treatment, Heart failure -- Exercise therapy, Heart failure -- Complications, Iron deficiency diseases -- Complications
Journal or Publication Title: European Journal of Heart Failure
Publisher: John Wiley & Sons, Ltd.
ISSN: 1879-0844
Official Date: May 2022
Dates:
DateEvent
May 2022Published
25 March 2022Available
22 March 2022Accepted
Volume: 24
Number: 5
Page Range: pp. 833-842
DOI: 10.1002/ejhf.2491
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access (Creative Commons)
Copyright Holders: © 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Date of first compliant deposit: 19 May 2022
Date of first compliant Open Access: 19 May 2022
RIOXX Funder/Project Grant:
Project/Grant IDRIOXX Funder NameFunder ID
UNSPECIFIEDVifor Pharmahttp://dx.doi.org/10.13039/501100006484
Is Part Of: 1
Related URLs:
  • http://creativecommons.org/licenses/by-n...

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us